On November 30, 2022, Zhejiang Difference Biological Technology Co., Ltd established its wholly-owned subsidiary, DIFFERENCE BIOTECH PTE. LTD. (hereinafter referred to as "Difference (Singapore)"), in Singapore. This subsidiary serves as a window to provide differentiated, high-value scientific and technological services and products to global clients. It is responsible for the internationalization of DIFF Biotech's products and technologies.

Founded in Hangzhou in 2017, DIFF Biotech is committed to building a world-class application platform for recombinant virus technology. The company focuses on differentiated innovation in areas such as genetic engineering vaccines for major infectious diseases, oncolytic viruses, viral vectors, mRNA delivery, virus tracing, and visual nucleic acid detection. After five years of dedicated development, DIFF Biotech has built a patent portfolio around its core technology platform, emphasizing first-in-class innovations and high-value patent applications while expanding into the global market. To date, the company has applied for nearly 40 invention patents, including more than 13 PCT international patents in Europe and the United States.